Ammonorhea

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Searching PubMed

amenorrhea evaluation management

Reading File
Reading File
Searching Images

amenorrhea evaluation algorithm flowchart diagnosis

A structured flowchart illustrating the patient selection process for a long-term COVID-19 follow-up study. The algorithm begins with an initial cohort of patients with a previously confirmed COVID-19 diagnosis who underwent clinical and paraclinical evaluation 2 years post-infection. Inclusion criteria are listed as age over 18 years and agreement to participate, resulting in an initial group of 156 patients. The flowchart then applies specific exclusion criteria, including severe heart failure (NYHA class 3-4), severe lung diseases (COPD GOLD stage 3-5, severe asthma, advanced interstitial lung disease), severe osteoarticular disease, autoimmune diseases, high thrombotic risk pathologies (pulmonary embolism, recent trauma/surgery), acute inflammatory diseases, and neuropsychiatric disorders. The final study group consists of 117 patients. The diagram uses purple rounded rectangles for criteria and blue rectangles for patient counts, connected by logical operators (+) and (-). An illustrative SARS-CoV-2 virion icon is included for thematic context. This flowchart is used to document study methodology in pulmonary rehabilitation and COVID-19 research.

A structured flowchart illustrating the patient selection process for a long-term COVID-19 follow-up study. The algorithm begins with an initial cohort of patients with a previously confirmed COVID-19 diagnosis who underwent clinical and paraclinical evaluation 2 years post-infection. Inclusion criteria are listed as age over 18 years and agreement to participate, resulting in an initial group of 156 patients. The flowchart then applies specific exclusion criteria, including severe heart failure (NYHA class 3-4), severe lung diseases (COPD GOLD stage 3-5, severe asthma, advanced interstitial lung disease), severe osteoarticular disease, autoimmune diseases, high thrombotic risk pathologies (pulmonary embolism, recent trauma/surgery), acute inflammatory diseases, and neuropsychiatric disorders. The final study group consists of 117 patients. The diagram uses purple rounded rectangles for criteria and blue rectangles for patient counts, connected by logical operators (+) and (-). An illustrative SARS-CoV-2 virion icon is included for thematic context. This flowchart is used to document study methodology in pulmonary rehabilitation and COVID-19 research.

Summary : This flowchart presents a diagnostic algorithm for idiopathic pulmonary fibrosis (IPF), detailing the stepwise evaluation of patients suspected of having IPF, including assessment of potential causes, imaging patterns, multidisciplinary discussion, and biopsy options.

flowchart:
# Nodes :
  • Patient suspected of having IPF (rectangle)
  • Potential cause/associated condition (rectangle)
  • Confirmation of specific diagnosis (including with HRCT) (rectangle)
  • Chest HRCT pattern (rounded rectangle)
  • UIP or probable UIP* (rectangle)
  • Indeterminate for UIP or alternate diagnosis (rectangle)
  • MDD (multidisciplinary discussion) (rounded rectangle, appears twice)
  • BAL† ± TBLC‡ (rectangle)
  • SLB‡ (rectangle)
  • IPF (rectangle)
  • Alternative diagnosis (rectangle)

# Connectors :
  • Patient suspected of having IPF → Potential cause/associated condition (down arrow)
  • Potential cause/associated condition → Confirmation of specific diagnosis (right arrow, labeled "Yes")
  • Confirmation of specific diagnosis → Alternative diagnosis (down arrow, labeled "Yes")
  • Potential cause/associated condition → Chest HRCT pattern (down arrow, labeled "No")
  • Chest HRCT pattern → UIP or probable UIP* (left branch)
  • Chest HRCT pattern → Indeterminate for UIP or alternate diagnosis (right branch)
  • UIP or probable UIP* → MDD (down arrow)
  • Indeterminate for UIP or alternate diagnosis → MDD (down arrow)
  • MDD → BAL† ± TBLC‡ (left branch)
  • MDD → SLB‡ (right branch)
  • BAL† ± TBLC‡ → MDD (dashed arrow to right, indicating possible subsequent step)
  • SLB‡ → MDD (down arrow)
  • MDD (second instance) → IPF (left arrow)
  • MDD (second instance) → Alternative diagnosis (right arrow)

# Layout :
  • The flowchart is organized top-to-bottom, with initial patient assessment at the top.
  • Branching occurs based on presence of potential cause/associated condition.
  • Imaging (HRCT) and diagnostic pattern assessment are central.
  • Multidisciplinary discussion (MDD) is a key decision node, leading to biopsy options.
  • Final outcomes are IPF or alternative diagnosis at the bottom.

# Analysis :
  • The algorithm emphasizes exclusion of known causes before considering IPF.
  • HRCT imaging pattern is pivotal in guiding further workup.
  • Multidisciplinary discussion is required for diagnosis, especially in cases with probable UIP pattern.
  • Biopsy options (BAL, TBLC, SLB) are considered for indeterminate cases, with iterative discussion.
  • The process is designed to minimize unnecessary invasive procedures and ensure accurate diagnosis.

Summary : This flowchart presents a diagnostic algorithm for idiopathic pulmonary fibrosis (IPF), detailing the stepwise evaluation of patients suspected of having IPF, including assessment of potential causes, imaging patterns, multidisciplinary discussion, and biopsy options. flowchart: # Nodes : • Patient suspected of having IPF (rectangle) • Potential cause/associated condition (rectangle) • Confirmation of specific diagnosis (including with HRCT) (rectangle) • Chest HRCT pattern (rounded rectangle) • UIP or probable UIP* (rectangle) • Indeterminate for UIP or alternate diagnosis (rectangle) • MDD (multidisciplinary discussion) (rounded rectangle, appears twice) • BAL† ± TBLC‡ (rectangle) • SLB‡ (rectangle) • IPF (rectangle) • Alternative diagnosis (rectangle) # Connectors : • Patient suspected of having IPF → Potential cause/associated condition (down arrow) • Potential cause/associated condition → Confirmation of specific diagnosis (right arrow, labeled "Yes") • Confirmation of specific diagnosis → Alternative diagnosis (down arrow, labeled "Yes") • Potential cause/associated condition → Chest HRCT pattern (down arrow, labeled "No") • Chest HRCT pattern → UIP or probable UIP* (left branch) • Chest HRCT pattern → Indeterminate for UIP or alternate diagnosis (right branch) • UIP or probable UIP* → MDD (down arrow) • Indeterminate for UIP or alternate diagnosis → MDD (down arrow) • MDD → BAL† ± TBLC‡ (left branch) • MDD → SLB‡ (right branch) • BAL† ± TBLC‡ → MDD (dashed arrow to right, indicating possible subsequent step) • SLB‡ → MDD (down arrow) • MDD (second instance) → IPF (left arrow) • MDD (second instance) → Alternative diagnosis (right arrow) # Layout : • The flowchart is organized top-to-bottom, with initial patient assessment at the top. • Branching occurs based on presence of potential cause/associated condition. • Imaging (HRCT) and diagnostic pattern assessment are central. • Multidisciplinary discussion (MDD) is a key decision node, leading to biopsy options. • Final outcomes are IPF or alternative diagnosis at the bottom. # Analysis : • The algorithm emphasizes exclusion of known causes before considering IPF. • HRCT imaging pattern is pivotal in guiding further workup. • Multidisciplinary discussion is required for diagnosis, especially in cases with probable UIP pattern. • Biopsy options (BAL, TBLC, SLB) are considered for indeterminate cases, with iterative discussion. • The process is designed to minimize unnecessary invasive procedures and ensure accurate diagnosis.

Summary : This flowchart presents an algorithm for the management of patients with suspected or confirmed ruptured abdominal aortic aneurysm (rAAA), outlining recommended time goals and stepwise clinical decision-making from emergency department arrival to surgical intervention.

flowchart:
# Nodes :
  • "Evaluation by an Emergency Physician of Any Patient Suspected of Having a Ruptured AAA" (rectangle)
  • "Diagnosis" (rectangle)
  • "Immediate Management" (rectangle)
  • "Consideration of Transfer to Regional Center" (rectangle)
  • Decision node: "If appropriate vascular services cannot be provided" (diamond; Yes/No branches)
  • "Rapid Transfer" (rectangle; Yes branch)
  • "Emergent Evaluation by Receiving Vascular Surgery Team" (rectangle; Yes branch)
  • "Emergent In-house Vascular Surgery Evaluation" (rectangle; No branch)
  • "Intervention by Vascular Surgery Team" (rectangle; both Yes/No branches converge here)

# Connectors :
  • Downward arrows connect each step sequentially.
  • From "Consideration of Transfer to Regional Center", a decision diamond splits into:
    – Yes: proceeds to "Rapid Transfer" → "Emergent Evaluation by Receiving Vascular Surgery Team"
    – No: proceeds to "Emergent In-house Vascular Surgery Evaluation"
  • Both branches converge at "Intervention by Vascular Surgery Team".

# Layout :
  • Vertical flow, top-to-bottom.
  • Decision diamond creates two parallel branches (Yes/No) that reconverge.
  • Time goals indicated on the left: "Emergency Department Door to Intervention = Less than 90 Minutes", with 30-minute intervals for each major step.

# Section Details :
## Evaluation by Emergency Physician :
  • Airway, Breathing, Circulation (ABC) protocol.
  • General assessment.
  • Vital sign monitoring.

## Diagnosis :
  • Clinical diagnosis criteria: Age > 50 with abdominal/back pain AND hypotension; known AAA with symptoms; hypotension or impending cardiovascular collapse.
  • Radiologic confirmation (ultrasound or CT) only if alternative diagnosis is likely.
  • Lab work/x-rays only to confirm rAAA.

## Immediate Management :
  • IV access with two large bore peripheral IVs.
  • Permissive hypotension (mental status and systolic pressure 70–90 mmHg).
  • Lab/x-ray only to confirm diagnosis.

## Consideration of Transfer to Regional Center :
  • Transfer if appropriate vascular services unavailable.
  • Transfer patients with good functional status and without severe comorbidity.
  • Patients who previously declined elective surgery should still be considered.
  • Discuss with receiving vascular surgeon: goals of care, comorbidities, hemodynamics.
  • Contraindication: ongoing cardiac arrest.

## Rapid Transfer (Yes branch) :
  • Physician-to-physician phone handoff.
  • Transfer images with patient if obtained.
  • In-transit care: vital sign monitoring, permissive hypotension.

## Emergent Evaluation by Receiving Vascular Surgery Team (Yes branch) :
  • Immediate evaluation upon arrival.

## Emergent In-house Vascular Surgery Evaluation (No branch) :
  • Immediate evaluation by in-house team.

## Intervention by Vascular Surgery Team :
  • Final step for both transfer and in-house pathways.

# Design Encodings :
  • Rectangular nodes for process steps.
  • Diamond node for decision point.
  • Bold red vertical bar on left indicating time goals.
  • Arrows for flow direction.
  • Text box at bottom: "Fig 5. Algorithm for management of the patient with a suspected or confirmed ruptured abdominal aortic aneurysm (AAA). CT, Computed tomography; IVs, intravenous lines."

# Analysis :
  • The algorithm emphasizes rapid assessment, diagnosis, and management, aiming for intervention within 90 minutes of emergency department arrival.
  • Decision logic prioritizes transfer to specialized centers if vascular services are unavailable, with clear criteria for transfer and contraindications.
  • Both transfer and in-house pathways converge on emergent surgical intervention, underscoring the urgency and standardized approach to rAAA management.
  • Time goals are visually reinforced, highlighting the importance of minimizing delays at each step.

Summary : This flowchart presents an algorithm for the management of patients with suspected or confirmed ruptured abdominal aortic aneurysm (rAAA), outlining recommended time goals and stepwise clinical decision-making from emergency department arrival to surgical intervention. flowchart: # Nodes : • "Evaluation by an Emergency Physician of Any Patient Suspected of Having a Ruptured AAA" (rectangle) • "Diagnosis" (rectangle) • "Immediate Management" (rectangle) • "Consideration of Transfer to Regional Center" (rectangle) • Decision node: "If appropriate vascular services cannot be provided" (diamond; Yes/No branches) • "Rapid Transfer" (rectangle; Yes branch) • "Emergent Evaluation by Receiving Vascular Surgery Team" (rectangle; Yes branch) • "Emergent In-house Vascular Surgery Evaluation" (rectangle; No branch) • "Intervention by Vascular Surgery Team" (rectangle; both Yes/No branches converge here) # Connectors : • Downward arrows connect each step sequentially. • From "Consideration of Transfer to Regional Center", a decision diamond splits into: – Yes: proceeds to "Rapid Transfer" → "Emergent Evaluation by Receiving Vascular Surgery Team" – No: proceeds to "Emergent In-house Vascular Surgery Evaluation" • Both branches converge at "Intervention by Vascular Surgery Team". # Layout : • Vertical flow, top-to-bottom. • Decision diamond creates two parallel branches (Yes/No) that reconverge. • Time goals indicated on the left: "Emergency Department Door to Intervention = Less than 90 Minutes", with 30-minute intervals for each major step. # Section Details : ## Evaluation by Emergency Physician : • Airway, Breathing, Circulation (ABC) protocol. • General assessment. • Vital sign monitoring. ## Diagnosis : • Clinical diagnosis criteria: Age > 50 with abdominal/back pain AND hypotension; known AAA with symptoms; hypotension or impending cardiovascular collapse. • Radiologic confirmation (ultrasound or CT) only if alternative diagnosis is likely. • Lab work/x-rays only to confirm rAAA. ## Immediate Management : • IV access with two large bore peripheral IVs. • Permissive hypotension (mental status and systolic pressure 70–90 mmHg). • Lab/x-ray only to confirm diagnosis. ## Consideration of Transfer to Regional Center : • Transfer if appropriate vascular services unavailable. • Transfer patients with good functional status and without severe comorbidity. • Patients who previously declined elective surgery should still be considered. • Discuss with receiving vascular surgeon: goals of care, comorbidities, hemodynamics. • Contraindication: ongoing cardiac arrest. ## Rapid Transfer (Yes branch) : • Physician-to-physician phone handoff. • Transfer images with patient if obtained. • In-transit care: vital sign monitoring, permissive hypotension. ## Emergent Evaluation by Receiving Vascular Surgery Team (Yes branch) : • Immediate evaluation upon arrival. ## Emergent In-house Vascular Surgery Evaluation (No branch) : • Immediate evaluation by in-house team. ## Intervention by Vascular Surgery Team : • Final step for both transfer and in-house pathways. # Design Encodings : • Rectangular nodes for process steps. • Diamond node for decision point. • Bold red vertical bar on left indicating time goals. • Arrows for flow direction. • Text box at bottom: "Fig 5. Algorithm for management of the patient with a suspected or confirmed ruptured abdominal aortic aneurysm (AAA). CT, Computed tomography; IVs, intravenous lines." # Analysis : • The algorithm emphasizes rapid assessment, diagnosis, and management, aiming for intervention within 90 minutes of emergency department arrival. • Decision logic prioritizes transfer to specialized centers if vascular services are unavailable, with clear criteria for transfer and contraindications. • Both transfer and in-house pathways converge on emergent surgical intervention, underscoring the urgency and standardized approach to rAAA management. • Time goals are visually reinforced, highlighting the importance of minimizing delays at each step.

Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive textbook content. Let me compile the full structured answer.

Amenorrhea

Definition

Amenorrhea is the absence of menstrual periods. Normal menstruation requires an intact HPO axis (hypothalamus - pituitary - ovary) plus a functional uterus and unobstructed outflow tract. Failure at any level causes amenorrhea.
  • Primary amenorrhea: Absence of menses by age 13 with no secondary sexual characteristics, or by age 15 with normal secondary sexual characteristics (2 standard deviations above the mean age of menarche). Failure to begin breast development by age 13 always warrants investigation.
  • Secondary amenorrhea: Absence of menstruation for 3 consecutive months (or 3 menstrual cycles) in a woman who previously menstruated. A woman with regular cycles whose period is even 1 week late warrants a pregnancy test. Fewer than 9 cycles/year or cycle length > 35 days also merits evaluation.
Berek & Novak's Gynecology, p. 1856 - it is important not to over-emphasize the distinction between primary and secondary amenorrhea because the causes substantially overlap.

Physiology of Normal Menstruation

For normal menstruation to occur:
  1. The hypothalamus must secrete GnRH in a pulsatile fashion.
  2. GnRH stimulates pituitary secretion of FSH and LH.
  3. FSH/LH promote ovarian follicular development and ovulation.
  4. The follicle secretes estrogen pre-ovulation; the corpus luteum secretes progesterone post-ovulation.
  5. Estrogen and progesterone cause endometrial development; their withdrawal triggers bleeding.
If any component (hypothalamus, pituitary, ovary, uterus, outflow tract) is non-functional, bleeding cannot occur.

WHO Classification

The WHO describes three classic groups, with a fourth added later:
WHO GroupTypeHormone Pattern
IHypogonadotropic hypogonadismNo estrogen, normal/low FSH, normal prolactin, no pituitary lesion
IINormogonadotropic anovulationEstrogen present, normal FSH and prolactin (e.g. PCOS)
IIIHypergonadotropic hypogonadismElevated FSH - gonadal insufficiency/failure
IV (added)Hyperprolactinemic anovulationAnovulation specifically due to hyperprolactinemia

Causes

Primary Amenorrhea

Causes Without Secondary Sexual Characteristics (never exposed to estrogen)
CategoryExamples
Hypergonadotropic hypogonadismTurner syndrome (45,X), gonadal dysgenesis (XO, XX), 17-hydroxylase deficiency, autoimmune oophoritis, resistant ovary syndrome, radiation/chemotherapy before puberty
Hypogonadotropic hypogonadismKallmann syndrome (GnRH deficiency + anosmia), craniopharyngioma, physiologic/constitutional delay, 5α-reductase deficiency, other genetic/CNS causes
Turner Syndrome is the most common cause of primary hypergonadotropic amenorrhea. Kallmann syndrome is the second most common hypothalamic cause - insufficient pulsatile GnRH, often associated with anosmia due to failure of neuronal migration during fetal development.
Causes With Secondary Sexual Characteristics (anatomy/outflow)
CategoryExamples
Outflow/Mullerian anomaliesImperforate hymen, transverse vaginal septum, Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome (vaginal/uterine agenesis)
Androgen insensitivityComplete androgen insensitivity (46,XY, female phenotype, breast development, absent pubic/axillary hair, blind vaginal pouch, no uterus)
Absent endometriumCongenitally absent endometrium (rare), Asherman syndrome
Complete Androgen Insensitivity - XY genotype, breast development due to peripheral aromatization of testosterone to estrogen, absent uterus and tubes (AMH from testes suppresses mullerian structures), testosterone in male range; X-linked recessive (androgen receptor gene on X chromosome).

Secondary Amenorrhea

The four most common causes of secondary amenorrhea are:
  1. Pregnancy/lactation (always rule out first)
  2. Hyperprolactinemia
  3. Thyroid disorders
  4. Iatrogenic (medications)
Comprehensive list by compartment:
Uterine (Outflow)
  • Asherman syndrome (intrauterine adhesions) - most common outflow cause; typically follows uterine curettage for pregnancy complications, myomectomy, or endometrial infection
  • Cervical stenosis post-cone biopsy/LEEP
Ovarian
  • PCOS (most common cause of secondary amenorrhea with eugonadotropic pattern)
  • Primary Ovarian Insufficiency (POI) - ovarian failure before age 40; associated with FMR1 premutation, chromosomal anomalies, autoimmune disease (20-40% of POI cases), chemotherapy (alkylating agents), radiation
  • Ovarian tumors
Adrenal
  • Late-onset congenital adrenal hyperplasia
  • Cushing syndrome
  • Virilizing adrenal tumors
  • Adrenocortical insufficiency
Thyroid
  • Hypothyroidism or hyperthyroidism
Pituitary
  • Hyperprolactinemia (prolactinoma most common)
  • Sheehan syndrome (postpartum pituitary necrosis)
  • Empty sella syndrome (reported in 4-16% of amenorrhea + galactorrhea cases)
  • Pituitary apoplexy
  • Acquired hypopituitarism
Hypothalamic (Functional)
  • Functional hypothalamic amenorrhea (FHA): stress, excessive exercise, weight loss, eating disorders (anorexia nervosa)
  • Tumor/infiltrative disease
Iatrogenic Drugs
  • Antipsychotics (phenothiazines, haloperidol, clozapine, pimozide) - raise prolactin
  • Antidepressants (TCAs, MAOIs)
  • Antihypertensives (calcium channel blockers, methyldopa, reserpine)
  • Drugs with estrogenic activity (digitalis, flavonoids, marijuana, OCP)
  • Cytotoxic agents (busulfan, chlorambucil, cisplatin, cyclophosphamide, fluorouracil)

Evaluation

History

  • Menstrual pattern history, weight changes, exercise habits, nutritional status
  • Galactorrhea, hot flashes, vaginal dryness (hypoestrogenism)
  • Hirsutism, acne (androgen excess)
  • Prior surgery, pelvic trauma, curettage
  • Medications, contraceptive history, chronic diseases
  • Headaches, visual field defects (pituitary tumor)

Physical Examination

  • Secondary sexual characteristics (breast development, pubic/axillary hair)
  • Visual fields, thyroid, cushingoid features
  • Galactorrhea
  • Abdominal/pelvic masses, clitoral enlargement
  • Signs of malnutrition

Laboratory - Initial (Mandatory Tests)

  1. β-hCG (serum or urine) - rule out pregnancy FIRST
  2. Serum TSH - screen for thyroid disease
  3. Serum prolactin (fasting, no recent breast stimulation, follicular phase if cycling)
  4. Serum FSH (+/- LH) - differentiates hypergonadotropic vs. hypogonadotropic vs. eugonadotropic
  5. Anti-Mullerian hormone (AMH) - optional; can support POI diagnosis (undetectable years before final menses)
  6. Vaginal ultrasound - assess antral follicle count (helps establish PCOS vs. POI diagnosis)

Interpretation of FSH

FSH LevelInterpretation
>25-40 mIU/mL (on ≥2 samples)Hypergonadotropic amenorrhea - ovarian insufficiency
Normal/lowHypogonadotropic or normogonadotropic - hypothalamic or pituitary cause

Further Testing Based on Clinical Suspicion

  • Karyotype: if POI in a woman < 25 or < 5 feet tall; also for primary amenorrhea with gonadal failure (high incidence of abnormal karyotype)
  • FMR1 (fragile X) premutation screening: all women with POI
  • MRI of sella turcica: if prolactin elevated, suspected pituitary/hypothalamic lesion, or unexplained hypothalamic amenorrhea with CNS symptoms
  • Pelvic/transvaginal ultrasound or MRI: anatomic evaluation for Mullerian anomalies
  • 24-hour urine cortisol or overnight dexamethasone suppression test: if Cushing syndrome suspected
  • GnRH stimulation test: differentiates hypothalamic from pituitary disease in gonadotropin deficiency
  • DEXA scan: bone mineral density if long-term hypoestrogenism is suspected
  • Autoimmune screen (21-hydroxylase antibodies, thyroid antibodies): in POI < 40 years (risk of autoimmune adrenal insufficiency)
  • Hysteroscopy: to confirm Asherman syndrome, resect adhesions

Progesterone Challenge Test

Administer progestogen (e.g. medroxyprogesterone 10 mg x 5-10 days):
  • Withdrawal bleed occurs = sufficient endogenous estrogen, no outflow obstruction. Likely hypothalamic dysfunction (stress, weight loss, exercise, progestin-dominant contraceptives).
  • No withdrawal bleed = measure FSH to localize: outflow problem (Asherman), severe hypoestrogenism, or need further workup.
Note: False positives and negatives are common with the progesterone challenge; modern guidelines suggest limited utility as a primary diagnostic tool (Berek & Novak's Gynecology, p. 1889).

Differential Diagnosis - FSH-Based Summary

CauseFSHLHE2Progestin Withdrawal
CNS/hypothalamic dysfunction (stress, exercise, weight loss)↓ or N↓ or N↓ or N±
Anorexia nervosa-
Hypothalamic lesions-
PCOSN or ↑N+
Hyperprolactinemia↓ or N↓ or N↓ or N±
Primary Ovarian Insufficiency↑↑-
Asherman syndromeNNN-

Treatment

Treatment is directed at the underlying cause. General principles include:

Specific Therapies

  • PCOS: Lifestyle modification, OCP for cycle regulation; letrozole or clomiphene for ovulation induction (letrozole now preferred as first-line - higher pregnancy and live birth rates)
  • Hyperprolactinemia: Dopamine agonists (cabergoline, bromocriptine)
  • Hypothyroidism: Levothyroxine
  • Asherman syndrome: Hysteroscopic adhesiolysis
  • Anatomic outflow obstruction (imperforate hymen, vaginal septum): Surgical correction
  • Functional hypothalamic amenorrhea: Nutritional rehabilitation, reduced exercise, stress management, cognitive behavioral therapy

Hormone Therapy (for hypoestrogenic states)

  • Estrogen (+/- progesterone) to initiate/maintain secondary sexual characteristics
  • Optimize bone mineral density - calcium and vitamin D supplementation, consider estrogen therapy for women with prolonged hypoestrogenism

Ovulation Induction (if fertility desired)

  • Letrozole (aromatase inhibitor, 2.5-5 mg x 5 days from day 3-5): Preferred first-line for PCOS; lower multiple pregnancy rate than clomiphene
  • Clomiphene citrate (50 mg x 5 days from day 3-5): Standard first choice for normogonadotropic anovulation with adequate estrogen and normal FSH/prolactin; up to 80% ovulation rate
  • Metformin + clomiphene: May improve ovulation in some PCOS patients
  • Pulsatile GnRH: For hypogonadotropic hypogonadism (hypothalamic cause)
  • Gonadotropins (FSH/LH injections): For pituitary or refractory hypothalamic causes
Berek & Novak's Gynecology, pp. 1856-1896; Tietz Textbook of Laboratory Medicine, 7th Edition, pp. 2353-2490

Key Points

  1. Primary amenorrhea is defined as no menses by age 13 (no secondary sexual characteristics) or age 15 (with normal secondary characteristics).
  2. Secondary amenorrhea = absence of menses for 3 months in a previously menstruating woman.
  3. Always rule out pregnancy first with serum/urine β-hCG.
  4. The four most common causes of secondary amenorrhea are pregnancy, hyperprolactinemia, thyroid disorders, and iatrogenic/medication-related causes.
  5. When gonadal failure accompanies primary amenorrhea, there is a high incidence of abnormal karyotype - karyotyping is mandatory.
  6. All women with POI should be screened for FMR1 premutation (fragile X carrier status).
  7. Prolonged hypoestrogenism causes bone loss - DEXA and supplementation are important.
  8. Do not over-emphasize the primary vs. secondary distinction - the causes substantially overlap.
This is a shared conversation. Sign in to Orris to start your own chat.